Therapeutic effects of serelaxin in acute heart failure: Necessity for bilateral research translation

Circulation Journal

Volumn 78, Issue 3, 2014, Pages 542-552

  Du, Xiao Jun ^a,b   Hewitson, Tim D ^c,d   Nguyen, My Nhan ^a,b   Samuel, Chrishan S ^b,d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Acute heart failure; Biomarkers; RELAX AHF; Relaxin; RXFP1

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ASPARTATE AMINOTRANSFERASE; CALCIUM ION; COLLAGEN; CREATININE; CYSTATIN C; ENDOTHELIN 1; GAP JUNCTION PROTEIN; GELATINASE A; GELATINASE B; H2 RELAXIN; HISTAMINE; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE SYNTHASE; NORADRENALIN; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RELAXIN IKE PEPTIDE RECEPTOR 1; SERELAXIN; SMAD2 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASOPRESSIN; RECOMBINANT PROTEIN; RELAXIN; SERELAXIN PROTEIN, HUMAN;

ACUTE HEART FAILURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENDOTHELIAL DYSFUNCTION; HEART INDEX; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; HOSPITAL READMISSION; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); NONHUMAN; ORGAN INJURY; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; SYSTEMIC VASCULAR RESISTANCE; TRANSLATIONAL RESEARCH; VASOCONSTRICTION; ACUTE DISEASE; HEART FAILURE; HOSPITALIZATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ACUTE DISEASE; CLINICAL TRIALS, PHASE III AS TOPIC; HEART FAILURE; HOSPITALIZATION; RECOMBINANT PROTEINS; RELAXIN;

EID: 84894492958     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0014     Document Type: Review

References (113)

1. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009; 53: 557-573.
2. Teerlink JR. Treatment of acutely decompensated heart failure. In: Greenberg BH, Barnard DD, Narayan SM, Teerlink JR, editors. Management of heart failure. 2010: 327-356.
3. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 116: 1482-1487.
4. Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, et al. Acute heart failure syndromes: Current state and framework for future research. Circulation 2005; 112: 3958-3968.
5. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: Lessons learned and directions forward. Circ Heart Fail 2010; 3: 314-325.
6. Vaduganathan M, Greene SJ, Ambrosy AP, Gheorghiade M, Butler J. The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol 2013; 10: 85-97.
7. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 363: 1419-1428.
8. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331.
9. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial. Lancet 2013; 381: 29-39.
10. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: Correlation with outcomes. J Am Coll Cardiol 2013; 61: 196-206.
11. Dschietzig T, Teichman S, Unemori E, Wood S, Boehmer J, Richter C, et al. Intravenous recombinant human relaxin in compensated heart failure: A safety, tolerability, and pharmacodynamic trial. J Card Fail 2009; 15: 182-190.
12. Debrah DO, Novak J, Matthews JE, Ramirez RJ, Shroff SG, Conrad KP. Relaxin is essential for systemic vasodilation and increased global arterial compliance during early pregnancy in conscious rats. Endocrinology 2006; 147: 5126-5131.
13. Conrad KP, Debrah DO, Novak J, Danielson LA, Shroff SG. Relaxin modifies systemic arterial resistance and compliance in conscious, nonpregnant rats. Endocrinology 2004; 145: 3289-3296.
14. Danielson LA, Sherwood OD, Conrad KP. Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest 1999; 103: 525-533.
15. Smith MC, Danielson LA, Conrad KP, Davison JM. Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. J Am Soc Nephrol 2006; 17: 3192-3197.
16. Baylis C. Relaxin may be the "elusive" renal vasodilatory agent of normal pregnancy. Am J Kidney Dis 1999; 34: 1142-1145.
17. Debrah DO, Debrah JE, Haney JL, McGuane JT, Sacks MS, Conrad KP, et al. Relaxin regulates vascular wall remodeling and passive mechanical properties in mice. J Appl Physiol 2011; 111: 260-271.
18. Conrad KP, Shroff SG. Effects of relaxin on arterial dilation, remodeling, and mechanical properties. Curr Hypertens Rep 2011; 13: 409-420.
19. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): A multicentre, randomised, placebocontrolled, parallel-group, dose-finding phase IIb study. Lancet 2009; 373: 1429-1439.
20. Ambrosy AP, Vaduganathan M, Huffman MD, Khan S, Kwasny MJ, Fought AJ, et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: An analysis of the EVEREST trial. Eur J Heart Fail 2012; 14: 302-311.
21. Gnanaraj JF, von Haehling S, Anker SD, Raj DS, Radhakrishnan J. The relevance of congestion in the cardio-renal syndrome. Kidney Int 2012; 83: 384-391.
22. Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A, et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 2013 November 18, doi:10.1093/eurheartj/eht459 [E-pub ahead of print].
23. Conrad KP. Maternal vasodilation in pregnancy: The emerging role relaxin. Am J Physiol Regul Integr Comp Physiol 2011; 301: R267-R275.
24. Segal MS, Sautina L, Li S, Diao Y, Agoulnik AI, Kielczewski J, et al. Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice. Blood 2012; 119: 629-636.
25. Novak J, Parry LJ, Matthews JE, Kerchner LJ, Indovina K, Hanley- Yanez K, et al. Evidence for local relaxin ligand-receptor expression and function in arteries. FASEB J 2006; 20: 2352-2362.
26. McGuane JT, Debrah JE, Sautina L, Jarajapu YP, Novak J, Rubin JP, et al. Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology 2011; 152: 2786-2796.
27. Jeyabalan A, Novak J, Doty KD, Matthews J, Fisher MC, Kerchner LJ, et al. Vascular matrix metalloproteinase-9 mediates the inhibition of myogenic reactivity in small arteries isolated from rats after short-term administration of relaxin. Endocrinology 2007; 148: 189-197.
28. Jeyabalan A, Kerchner LJ, Fisher MC, McGuane JT, Doty KD, Conrad KP. Matrix metalloproteinase-2 activity, protein, mRNA, and tissue inhibitors in small arteries from pregnant and relaxin-treated nonpregnant rats. J Appl Physiol 2006; 100: 1955-1963.
29. Jelinic M, Leo CH, Post Uiterweer ED, Sandow SL, Gooi JH, Wlodek ME, et al. Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment. FASEB J 2013; 28: 275-287.
30. Li Y, Negishi S, Sakamoto M, Usas A, Huard J. The use of relaxin improves healing in injured muscle. Ann NY Acad Sci 2005; 1041: 395-397.
31. Xu Q, Chakravorty A, Bathgate RA, Dart AM, Du XJ. Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats. Hypertension 2010; 55: 1260-1266.
32. Allen LA, Hernandez AF, O'Connor CM, Felker GM. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol 2009; 53: 2248-2258.
33. Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ. Cardiovascular effects of relaxin: From basic science to clinical therapy. Nat Rev Cardiol 2010; 7: 48-58.
34. Lekgabe ED, Kiriazis H, Zhao C, Xu Q, Moore XL, Su Y, et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 2005; 46: 412-418.
35. Parikh A, Patel D, McTiernan CF, Xiang W, Haney J, Yang L, et al. Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts. Circ Res 2013; 113: 313-321.
36. Samuel CS, Hewitson TD, Zhang Y, Kelly DJ. Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. Endocrinology 2008; 149: 3286-3293.
37. Samuel CS, Unemori EN, Mookerjee I, Bathgate RA, Layfield SL, Mak J, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2004; 145: 4125-4133.
38. Bathgate RA, Lekgabe ED, McGuane JT, Su Y, Pham T, Ferraro T, et al. Adenovirus-mediated delivery of relaxin reverses cardiac fibrosis. Mol Cell Endocrinol 2008; 280: 30-38.
39. Bathgate RA, Halls ML, van der Westhuizen ET, Callander GE, Kocan M, Summers RJ. Relaxin family peptides and their receptors. Physiol Rev 2013; 93: 405-480.
40. Samuel CS, Du XJ, Bathgate RA, Summers RJ. 'Relaxin' the stiffened heart and arteries: The therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharmacol Ther 2006; 112: 529-552.
41. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007; 117: 568-575.
42. Mookerjee I, Hewitson TD, Halls ML, Summers RJ, Mathai ML, Bathgate RA, et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J 2009; 23: 1219-1229.
43. Nguyen TP, Xie Y, Garfinkel A, Qu Z, Weiss JN. Arrhythmogenic consequences of myofibroblast-myocyte coupling. Cardiovasc Res 2012; 93: 242-251.
44. Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res 2011; 89: 744-753.
45. He K, Shi X, Zhang X, Dang S, Ma X, Liu F, et al. Long-distance intercellular connectivity between cardiomyocytes and cardiofibroblasts mediated by membrane nanotubes. Cardiovasc Res 2011; 92: 39-47.
46. Miragoli M, Gaudesius G, Rohr S. Electrotonic modulation of cardiac impulse conduction by myofibroblasts. Circ Res 2006; 98: 801-810.
47. Miragoli M, Salvarani N, Rohr S. Myofibroblasts induce ectopic activity in cardiac tissue. Circ Res 2007; 101: 755-758.
48. Rosker C, Salvarani N, Schmutz S, Grand T, Rohr S. Abolishing myofibroblast arrhythmogeneicity by pharmacological ablation of alpha-smooth muscle actin containing stress fibers. Circ Res 2011; 109: 1120-1131.
49. Bani D, Masini E, Bello MG, Bigazzi M, Sacchi TB. Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart. Am J Pathol 1998; 152: 1367-1376.
50. Formigli L, Francini F, Nistri S, Margheri M, Luciani G, Naro F, et al. Skeletal myoblasts overexpressing relaxin improve differentiation and communication of primary murine cardiomyocyte cell cultures. J Mol Cell Cardiol 2009; 47: 335-345.
51. Samuel CS, Cendrawan S, Gao XM, Ming Z, Zhao C, Kiriazis H, et al. Relaxin remodels fibrotic healing following myocardial infarction. Lab Invest 2011; 91: 675-690.
52. Moore XL, Tan SL, Lo CY, Fang L, Su YD, Gao XM, et al. Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes. Endocrinology 2007; 148: 1582-1589.
53. Zhang J, Qi YF, Geng B, Pan CS, Zhao J, Chen L, et al. Effect of relaxin on myocardial ischemia injury induced by isoproterenol. Peptides 2005; 26: 1632-1639.
54. Gu HP, Lin S, Xu M, Yu HY, Du XJ, Zhang YY, et al. Up-regulating relaxin expression by G-quadruplex interactive ligand to achieve antifibrotic action. Endocrinology 2012; 153: 3692-3700.
55. Sandek A, Bjarnason I, Volk H-D, Crane R, Meddings JB, Niebauer J, et al. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol 2012; 157: 80-85.
56. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 2005; 26: 2368-2374.
57. Verbrugge FH, Dupont M, Steels P, Grieten L, Malbrain M, Tang WH, et al. Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol 2013; 62: 485-495.
58. Poole DC, Hirai DM, Copp SW, Musch TI. Muscle oxygen transport and utilization in heart failure: Implications for exercise (in) tolerance. Am J Physiol Heart Circ Physiol 2012; 302: H1050-H1063.
59. Herrmann J, Kaski JC, Lerman A. Coronary microvascular dysfunction in the clinical setting: From mystery to reality. Eur Heart J 2012; 33: 2771-2782b.
60. De Backer D, Creteur J, Dubois MJ, Sakr Y, Vincent JL. Microvascular alterations in patients with acute severe heart failure and cardiogenic shock. Am Heart J 2004; 147: 91-99.
61. Hogan CJ, Ward KR, Kontos MC, Thacker LR, Pittman R. Peripheral tissue oxygenation improves during ED treatment of acute heart failure. Am J Emerg Med 2012; 30: 196-202.
62. den Uil CA, Lagrand WK, Spronk PE, van der Ent M, Jewbali LS, Brugts JJ, et al. Low-dose nitroglycerin improves microcirculation in hospitalized patients with acute heart failure. Eur J Heart Fail 2009; 11: 386-390.
63. Lauten A, Ferrari M, Goebel B, Rademacher W, Schumm J, Uth O, et al. Microvascular tissue perfusion is impaired in acutely decompensated heart failure and improves following standard treatment. Eur J Heart Fail 2011; 13: 711-717.
64. Brecht A, Bartsch C, Baumann G, Stangl K, Dschietzig T. Relaxin inhibits early steps in vascular inflammation. Regul Pept 2011; 166: 76-82.
65. Csiszar A, Wang M, Lakatta EG, Ungvari Z. Inflammation and endothelial dysfunction during aging: Role of NF-kappaB. J Appl Physiol 2008; 105: 1333-1341.
66. Li M, Fukagawa NK. Age-related changes in redox signaling and VSMC function. Antioxid Redox Signal 2010; 12: 641-655.
67. Mu X, Urso ML, Murray K, Fu F, Li Y. Relaxin regulates MMP expression and promotes satellite cell mobilization during muscle healing in both young and aged mice. Am J Pathol 2010; 177: 2399-2410.
68. Hewitson TD, Ho WY, Samuel CS. Antifibrotic properties of relaxin: In vivo mechanism of action in experimental renal tubulointerstitial fibrosis. Endocrinology 2010; 151: 4938-4948.
69. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost- Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010; 376: 875-885.
70. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al; SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA 2007; 297: 1883-1891.
71. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, et al. Clinical outcome endpoints in heart failure trials: A European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail 2013; 15: 1082-1094.
72. Chow BS, Chew EG, Zhao C, Bathgate RA, Hewitson TD, Samuel CS. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMPdependent pathway to up-regulate matrix metalloproteinases: The additional involvement of iNOS. PLoS One 2012; 7: e42714, doi:10.1371/journal.pone.0042714.
73. Debrah DO, Conrad KP, Jeyabalan A, Danielson LA, Shroff SG. Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension 2005; 46: 745-750.
74. Dschietzig T, Bartsch C, Kinkel T, Baumann G, Stangl K. Myocardial relaxin counteracts hypertrophy in hypertensive rats. Ann NY Acad Sci 2005; 1041: 441-443.
75. Chan LJ, Rosengren KJ, Layfield SL, Bathgate RA, Separovic F, Samuel CS, et al. Identification of key residues essential for the structural fold and receptor selectivity within the A-chain of human gene-2 (H2) relaxin. J Biol Chem 2012; 287: 41152-41164.
76. Masini E, Zagli G, Ndisang JF, Solazzo M, Mannaioni PF, Bani D. Protective effect of relaxin in cardiac anaphylaxis: Involvement of the nitric oxide pathway. Br J Pharmacol 2002; 137: 337-344.
77. Masini E, Bani D, Bello MG, Bigazzi M, Mannaioni PF, Sacchi TB. Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: Evidence for an involvement of nitric oxide. Endocrinology 1997; 138: 4713-4720.
78. Perna AM, Masini E, Nistri S, Briganti V, Chiappini L, Stefano P, et al. Novel drug development opportunity for relaxin in acute myocardial infarction: Evidences from a swine model. FASEB J 2005; 19: 1525-1527.
79. Nistri S, Cinci L, Perna AM, Masini E, Mastroianni R, Bani D. Relaxin induces mast cell inhibition and reduces ventricular arrhythmias in a swine model of acute myocardial infarction. Pharmacol Res 2008; 57: 43-48.
80. Formigli L, Perna AM, Meacci E, Cinci L, Margheri M, Nistri S, et al. Paracrine effects of transplanted myoblasts and relaxin on postinfarction heart remodelling. J Cell Mol Med 2007; 11: 1087-1100.
81. Bonacchi M, Nistri S, Nanni C, Gelsomino S, Pini A, Cinci L, et al. Functional and histopathological improvement of the post-infarcted rat heart upon myoblast cell grafting and relaxin therapy. J Cell Mol Med 2009; 13: 3437-3448.
82. Di Lascio G, Harmelin G, Targetti M, Nanni C, Bianchi G, Gasbarri T, et al. Cellular retrograde cardiomyoplasty and relaxin therapy for postischemic myocardial repair in a rat model. Tex Heart Inst J 2012; 39: 488-499.
83. Bonner JS, Lantier L, Hocking KM, Kang L, Owolabi M, James FD, et al. Relaxin treatment reverses insulin resistance in mice fed a highfat diet. Diabetes 2013; 62: 3251-3260.
84. Samuel CS, Zhao C, Bond CP, Hewitson TD, Amento EP, Summers RJ. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis. Kidney Int 2004; 65: 2054-2064.
85. Samuel CS, Lin F, Hossain MA, Zhao C, Ferraro T, Bathgate RA, et al. Improved chemical synthesis and demonstration of the relaxin receptor binding affinity and biological activity of mouse relaxin. Biochemistry 2007; 46: 5374-5381.
86. Danielson LA, Welford A, Harris A. Relaxin improves renal function and histology in aging Munich Wistar rats. J Am Soc Nephrol 2006; 17: 1325-1333.
87. Garber SL, Mirochnik Y, Brecklin CS, Unemori EN, Singh AK, Slobodskoy L, et al. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease 1. Kidney Int 2001; 59: 876-882.
88. McDonald GA, Sarkar P, Rennke H, Unemori E, Kalluri R, Sukhatme VP. Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo. Am J Physiol Renal Physiol 2003; 285: F59-F67.
89. Garber SL, Mirochnik Y, Brecklin C, Slobodskoy L, Arruda JA, Dunea G. Effect of relaxin in two models of renal mass reduction. Am J Nephrol 2003; 23: 8-12.
90. Sasser JM, Molnar M, Baylis C. Relaxin ameliorates hypertension and increases NO metabolite excretion in angiotensin II but not LNAME hypertensive rats. Hypertension 2011; 58: 197-204.
91. Yoshida T, Kumagai H, Suzuki A, Kobayashi N, Ohkawa S, Odamaki M, et al. Relaxin ameliorates salt-sensitive hypertension and renal fibrosis. Nephrol Dial Transplant 2012; 27: 2190-2197.
92. Yoshida T, Kumagai H, Kohsaka T, Ikegaya N. Relaxin protects against renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2013; 305: F1169-F1176.
93. Collino M, Rogazzo M, Pini A, Benetti E, Rosa AC, Chiazza F, et al. Acute treatment with relaxin protects the kidney against ischaemia/ reperfusion injury. J Cell Mol Med 2013; 17: 1494-1505.
94. Wong S, Samuel C, Kelly D, Zhang Y, Becker G, Hewitson T. The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes. Protein Pept Lett 2013; 20: 1029-1038.
95. Samuel CS, Zhao C, Bathgate RA, Bond CP, Burton MD, Parry LJ, et al. Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis. FASEB J 2003; 17: 121-123.
96. Kenyon NJ, Ward RW, Last JA. Airway fibrosis in a mouse model of airway inflammation. Toxicol Appl Pharmacol 2003; 186: 90-100.
97. Royce SG, Miao YR, Lee M, Samuel CS, Tregear GW, Tang ML. Relaxin reverses airway remodeling and airway dysfunction in allergic airways disease. Endocrinology 2009; 150: 2692-2699.
98. Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH, Erikson ME, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996; 98: 2739-2745.
99. Huang X, Gai Y, Yang N, Lu B, Samuel CS, Thannickal VJ, et al. Relaxin regulates myofibroblast contractility and protects against lung fibrosis. Am J Pathol 2011; 179: 2751-2765.
100. Tozzi CA, Poiani GJ, McHugh NA, Shakarjian MP, Grove BH, Samuel CS, et al. Recombinant human relaxin reduces hypoxic pulmonary hypertension in the rat. Pulm Pharmacol Ther 2005; 18: 346-353.
101. Alexiou K, Matschke K, Westphal A, Stangl K, Dschietzig T. Relaxin is a candidate drug for lung preservation: Relaxin-induced protection of rat lungs from ischemia-reperfusion injury. J Heart Lung Transplant 2010; 29: 454-460.
102. Alexiou K, Wilbring M, Matschke K, Dschietzig T. Relaxin protects rat lungs from ischemia-reperfusion injury via inducible NO synthase: Role of ERK-1/2, PI3K, and Forkhead transcription factor FKHRL1. PLoS ONE 2013; 8: e75592, doi:10.1371/journal.pone.0075592.
103. Williams EJ, Benyon RC, Trim N, Hadwin R, Grove BH, Arthur MJ, et al. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 2001; 49: 577-583.
104. Bennett RG, Heimann DG, Singh S, Simpson RL, Tuma DJ. Relaxin decreases the severity of established hepatic fibrosis in mice. Liver Int 2013 June 16, doi:10.1111/liv.12247 [E-pub ahead of print].
105. Boehnert MU, Hilbig H, Armbruster FP. Relaxin as an additional protective substance in preserving and reperfusion solution for liver transplantation, shown in a model of isolated perfused rat liver. Ann NY Acad Sci 2005; 1041: 434-440.
106. Boehnert MU, Armbruster FP, Hilbig H. Relaxin as a protective substance in the preserving solution for liver transplantation: Spectrophotometric in vivo imaging of local oxygen supply in an isolated perfused rat liver model. Ann NY Acad Sci 2009; 1160: 320-321.
107. Fallowfield J, Hayden A, Snowdon V, Aucott R, Stutchfield B, Mole D, et al. Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo. Hepatology 2013 July 19, doi:10.1002/hep.26627 [E-pub ahead of print].
108. Masini E, Cuzzocrea S, Mazzon E, Muia C, Vannacci A, Fabrizi F, et al. Protective effects of relaxin in ischemia/reperfusion-induced intestinal injury due to splanchnic artery occlusion. Br J Pharmacol 2006; 148: 1124-1132.
109. Baccari MC, Nistri S, Vannucchi MG, Calamai F, Bani D. Reversal by relaxin of altered ileal spontaneous contractions in dystrophic (mdx) mice through a nitric oxide-mediated mechanism. Am J Physiol Regul Integr Comp Physiol 2007; 293: R662-R668.
110. Cosen-Binker LI, Binker MG, Cosen R, Negri G, Tiscornia O. Relaxin prevents the development of severe acute pancreatitis. World J Gastroenterol 2006; 12: 1558-1568.
111. Negishi S, Li Y, Usas A, Fu FH, Huard J. The effect of relaxin treatment on skeletal muscle injuries. Am J Sports Med 2005; 33: 1816-1824.
112. Willcox JM, Summerlee AJ, Murrant CL. Relaxin induces rapid, transient vasodilation in the microcirculation of hamster skeletal muscle. J Endocrinol 2013; 218: 179-191.
113. Roche PJ, Crawfourd RJ, Tregear GW. A single-copy relaxin-like gene sequence is present in sheep. Mol Cell Endocrinol 1993: 91: 21-28.